Table 2.
Tyrosine kinase and mTOR inhibitor target expression in primary and metastatic RCC samples
| Target | AQUA scores, primary specimens (mean ± SD) | AQUA scores, metastatic specimens (mean ± SD) | t-statistic | p-value |
|---|---|---|---|---|
| B-Raf |
32.1 ± 8.9 |
31.2 ± 10.2 |
−0.417 |
0.678 |
| C-Raf |
26.7 ± 2.1 |
28.4 ± 2.5 |
0.519 |
0.605 |
| cKit |
23.3 ± 1.3 |
23.4 ± 1.3 |
0.079 |
0.937 |
| FGF-R1 |
29.1 ± 1.1 |
29.9 ± 0.9 |
0.579 |
0.564 |
| HIF-2α |
58.2 ± 1.9 |
58.2 ± 2.0 |
0.014 |
0.989 |
| mTOR |
18.8 ± 1.4 |
22.4 ± 1.8 |
1.637 |
0.106 |
| PDGF-Rβ |
24.7 ± 0.9 |
27.9 ± 1.5 |
1.879 |
0.064 |
| VEGF-R1 |
22.6 ± 0.9 |
23.9 ± 1.2 |
0.34 |
0.735 |
| VEGF-R2 |
36.5 ± 2.4 |
33.5 ± 1.7 |
−1.294 |
0.200 |
| VEGF-R3 |
45.6 ± 2.0 |
46.5 ± 1.6 |
0.371 |
0.712 |
| VEGF |
24.7 ± 1.0 |
26.0 ± 1.1 |
0.907 |
0.367 |
| VEGF-B |
11.2 ± 0.6 |
11.8 ± 0.9 |
0.486 |
0.628 |
| VEGF-C |
17.0 ± 1.3 |
14.3 ± 1.2 |
−1.544 |
0.127 |
| VEGF-D |
35.0 ± 1.2 |
36.8 ± 1.3 |
1.018 |
0.312 |
| MEK1 |
37.5 ± 2.5 |
50.3 ± 3.1 |
3.183 |
0.002 |
| ERK1/2 | 17.0 ± 1.1 | 18.6 ± 1.7 | 0.802 | 0.425 |